Global X Genomics & Biotechnology ETF (NASDAQ: GNOM)

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM), Quote.Headers.trade-ideas

Healthcare

The Fund invests at least 80 percent of its total assets in the securities of the Solactive Genomics Index (Underlying Index). The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received).

Alnylam Pharmaceuticals Inc.

Avidity Biosciences Inc

Bio-Techne Corp

Legend Biotech Corp

Arrowhead Pharmaceuticals Inc

Intellia Therapeutics Inc

Myriad Genetics Inc

Sarepta Therapeutics Inc

Natera Inc

Moderna Inc

Veracyte, Inc.

Agilent Technologies Inc

Biontech Se Adr

Qiagen N.V.

Illumina, Inc.

Biomarin Pharmaceutical Inc.

Crispr Therapeutics Ag

Beam Therapeutics Inc

Genscript Biotech Corp

Global X Genomics & Biotechnology ETF

Stuttgart,,Germany,-,01-19-2021:,Logo,Of,Dutch,Sample,And,Assay

Earnings

Equities

Mid Cap

News

Guidance

Movers

GNOM

QGEN

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

Biotech

Long Ideas

Sector ETFs

Trading Ideas

ETFs

General

ARKG

MRNA

AKRG

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

Comments

Global X Genomics & Biotechnology ETF

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM), Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell